Document:

EX-10.34

 Exhibit 10.34 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, TRANSFERRED OR
HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT AGREEMENT 

To Purchase Shares of Preferred Stock of 
 REVANCE THERAPEUTICS, INC. 
 Dated as of
[            ] (the “Effective Date”) 
 WHEREAS,
ReVance Therapeutics, Inc., a Delaware corporation (the “Company”), has entered into a Loan and Security Agreement of even date herewith (the “Loan Agreement”) with Hercules Technology Growth Capital, Inc., a Maryland corporation
(the “Warrantholder”); 
 WHEREAS, the Company desires to grant to Warrantholder, in consideration for, among other
things, the financial accommodations provided for in the Loan Agreement, the right to purchase shares of its Preferred Stock pursuant to this Warrant Agreement (the “Agreement”); 

NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan Agreement and providing the financial
accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 
 SECTION 1. GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 
 For value
received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase, from the Company, the Designated Warrant Number (as
defined below) of fully paid and non-assessable shares of the Preferred Stock (as defined below) at the Exercise Price (as defined below). The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As used
herein, the following terms shall have the following meanings: 
 “Acquisition” means any consolidation or
merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in which the stockholders of the Company (in the aggregate) immediately prior to such consolidation, merger or reorganization,
own less than fifty percent (50%) of the voting power of the surviving entity immediately after such consolidation, merger or reorganization; or (B) any transaction or series of related transactions to which the Company is a party in which
in excess of fifty percent (50%) of the Company’s voting power is transferred; provided that none of the following shall constitute an Acquisition: (i) any consolidation or merger effected exclusively to change the domicile of the
Company, (ii) any transaction or series 

  
 1 

 
of transactions principally for bona fide equity financing purposes in which cash is received by the Company, (iii) the cancellation or conversion of indebtedness or a combination thereof
pursuant to the Company’s Note and Warrant Purchase Agreement dated as of January 24, 2011, or (iv) an Initial Public Offering. 
 “Act” means the Securities Act of 1933, as amended. 

“Asset Transfer” means a sale, lease or other disposition of all or substantially all of the assets of the Company.

 “Charter” means the Company’s Articles of Incorporation, Certificate of Incorporation or other
constitutional document, as may be amended from time to time. 
 “Common Stock” means the Company’s common
stock, $0.001 par value per share. 
 “Designated Warrant Number” means the quotient of the Warrant Coverage
divided by the Exercise Price, which quotient, if not a whole number, shall be rounded down to the nearest whole number. 

“Exercise Price” means a purchase price of either of the following, as applicable: (a) if the Warrant is exercised
with respect to Series D Preferred Stock, $4.450 per share, or (b) if the Warrant is exercised with respect to a Subsequent Round, the price per share of Preferred Stock in such Subsequent Round. 

“Initial Public Offering” means the initial underwritten public offering of the Company’s Common Stock pursuant to a
registration statement under the Act, which public offering has been declared effective by the Securities and Exchange Commission (“SEC”); 
 “Merger Event” means an Acquisition or Asset Transfer. 

“Preferred Stock” means at Warrantholder’s option (a) the Series D Preferred Stock of the Company and any other
stock into or for which the Series D Preferred Stock may be converted or exchanged, or (b) shares of preferred stock of the Company issued in a Subsequent Round and any other stock into or for which such preferred stock may be converted or
exchanged, and, in the case of each of (a) and (b), upon and after the occurrence of an event which results in the automatic or voluntary conversion, redemption or retirement of all (but not less than all) of the outstanding shares of such
Preferred Stock, including, without limitation, the consummation of an Initial Public Offering of the Common Stock in which such a conversion occurs, then from and after the date upon which such outstanding shares are so converted, redeemed or
retired, “Preferred Stock” shall mean such Common Stock. 
 “Purchase Price” means, with respect to
any exercise of this Agreement, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Preferred Stock requested to be exercised under this Agreement pursuant to such exercise. 

“Series Preferred” means Series Preferred, as defined in the Charter. 

“Subsequent Round” means the closing of any equity financing by the Company, which becomes effective after the closing of
the Series D Preferred Stock financing (which, for the sake of clarity, shall not include any closing of the Company’s convertible debt 

  
 2 

 
financing pursuant to the Company’s Note and Warrant Purchase Agreement dated as of January 24, 2011). 
 “Warrant Coverage” means $1,200,000. 
 SECTION 2. TERM OF
THE AGREEMENT. 
 Except as otherwise provided for herein, the term of this Agreement and the right to purchase Preferred Stock
as granted herein (the “Warrant) shall commence on the Effective Date and shall be exercisable for a period ending upon (a) the later to occur of (i) ten (10) years from the Effective Date; or (ii) five (5) years after
the Initial Public Offering; or (b) immediately prior to a Merger Event if the consideration payable to the holders of Company capital stock is cash or stock of a publicly traded company, that is registered under the Act and not subject to a
Market Stand-Off (as defined in Section 10(g)) or similar provision, or a combination thereof (a “Qualifying Merger Event”). 
 SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 
 (a) Exercise. The
purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal
office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance
with the terms set forth below, and in no event later than three (3) days thereafter, the Company shall issue to the Warrantholder a certificate for the number of shares of Preferred Stock purchased and shall execute the acknowledgment of
exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future purchases, if any. 

The Purchase Price may be paid at the Warrantholder’s election either (i) by cash or check, or (ii) by surrender of all or
a portion of the Warrant for shares of Preferred Stock to be exercised under this Agreement and, if applicable, an amended Agreement representing the remaining number of shares purchasable hereunder, as determined below (“Net
Issuance”). If the Warrantholder elects the Net Issuance method, the Company will issue Preferred Stock in accordance with the following formula: 
  

					
		  		  	 X = Y(A-B)

            A

			
	Where:	  	X =	  	the number of shares of Preferred Stock to be issued to the Warrantholder.
			
		  		  	            Y = the number of shares of Preferred Stock requested to be exercised under this Agreement.
			
		  		  	            A = the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of
Preferred Stock.
			
		  	B =	  	the Exercise Price.

 For purposes of the above calculation, current fair market value of Preferred Stock shall mean with respect to each share
of Preferred Stock: 

  
 3 

 (i) if the exercise is in connection with an Initial Public Offering, and if
the Company’s Registration Statement relating to such Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public” of the Common
Stock specified in the final prospectus with respect to the offering and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 

(ii) if the exercise is after, and not in connection with an Initial Public Offering, and: 

(A) if the Common Stock is traded on a securities exchange, the fair market value shall be deemed to be the product of
(x) the average of the closing prices over a five (5) day period ending three days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share
of Preferred Stock is convertible at the time of such exercise; or 
 (B) if the Common Stock is traded
over-the-counter, the fair market value shall be deemed to be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending three days before the day
the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 

(iii) if at any time the Common Stock is not listed on any securities exchange or quoted in the NASDAQ National Market or
the over-the-counter market, the current fair market value of Preferred Stock shall be the product of (x) the highest price per share which the Company could obtain from a willing buyer (not a current employee or director) for shares of Common
Stock sold by the Company, from authorized but unissued shares, as determined in good faith by its Board of Directors and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such
exercise, unless the Company shall become subject to a Merger Event, in which case the fair market value of Preferred Stock shall be deemed to be the per share value received by the holders of the Company’s Preferred Stock on a common
equivalent basis pursuant to such Merger Event. 
 Upon partial exercise by either cash or Net Issuance, the Company shall
promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective
Date hereof. 
 (b) Exercise Prior to Expiration. To the extent this Agreement is not previously exercised as to all
Preferred Stock subject hereto, and if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically exercised pursuant to Section 3(a) (even if not
surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Preferred Stock upon such expiration shall be determined pursuant to Section 3(a). To the extent this Agreement
or any portion thereof is deemed automatically exercised pursuant to this Section 

  
 4 

 
3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if any, the Warrantholder is to receive by reason of such automatic exercise. 

SECTION 4. RESERVATION OF SHARES. 
 During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Preferred Stock to provide for the exercise of the rights to purchase
Preferred Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of its Common Stock to provide for the conversion of the Preferred Shares available hereunder. 

SECTION 5. NO FRACTIONAL SHARES OR SCRIP. 
 No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares the Company shall make a cash payment therefor upon
the basis of the Exercise Price then in effect. 
 SECTION 6. NO RIGHTS AS SHAREHOLDER/STOCKHOLDER. 

This Agreement does not entitle the Warrantholder to any voting rights or other rights as a shareholder/stockholder of the Company prior
to the exercise of this Agreement. 
 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Warrantholder’s
initial address, for purposes of such registry, is set forth below Warrantholder’s signature on this Agreement. Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 
 The Exercise Price and the number of shares of Preferred Stock purchasable hereunder are subject to adjustment, as follows: 
 (a) Merger Event. If at any time there shall be Merger Event (other than a Qualifying Merger Event), then, as a part of such Merger Event, lawful provision shall be made so that the Warrantholder
shall thereafter be entitled to receive, upon exercise of this Agreement, the number of shares of preferred stock or other securities or property of the successor corporation resulting from such Merger Event that would have been issuable if
Warrantholder had exercised this Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of
this Agreement with respect to the rights and interests of the Warrantholder after the Merger Event to the end that the provisions of this Agreement (including adjustments of the Exercise Price and number of shares of Preferred Stock purchasable)
shall be applicable in their entirety, and to the greatest extent possible. Without limiting the foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of this
Agreement. In connection with a Merger Event and upon Warrantholder’s written election to the Company, the Company shall cause this Warrant Agreement to be exchanged for the consideration that Warrantholder would have received if Warrantholder
chose to exercise its right to have shares issued pursuant to the Net Issuance provisions of this Warrant Agreement without actually exercising such right, acquiring such shares and exchanging such shares for such consideration 

  
 5 

 (b) Reclassification of Shares. Except as set forth in Section 8(a), if the
Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of
any other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase
rights under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. 

(c) Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Preferred Stock, (i) in
the case of a subdivision, the Exercise Price shall be proportionately decreased, and the number of shares of Preferred Stock issuable upon exercise of this Agreement shall be proportionately increased, or (ii) in the case of a combination, the
Exercise Price shall be proportionately increased, and the number of shares of Preferred Stock issuable upon the exercise of this Agreement shall be proportionately decreased. 
 (d) Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall: 
 (i) pay a dividend with respect to the Preferred Stock payable in Preferred Stock, then the Exercise Price shall be adjusted, from and after the date of determination of shareholders/stockholders entitled
to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of
Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Preferred Stock outstanding immediately after such dividend or distribution; or 

(ii) make any other distribution with respect to Preferred Stock (or stock into which the Preferred Stock is convertible),
except any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a
proportionate share of any such distribution as though it were the holder of the Preferred Stock (or other stock for which the Preferred Stock is convertible) as of the record date fixed for the determination of the shareholders/stockholders of the
Company entitled to receive such distribution. 
 (e) Antidilution Rights. Antidilution rights applicable to the Preferred
Stock purchasable hereunder are as set forth in the Company’s Charter and shall be applicable with respect to the Preferred Stock issuable hereunder. The Company shall promptly provide the Warrantholder with any restatement, amendment,
modification or waiver of the Charter; provided, that no such amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Preferred Stock as of the date hereof unless such amendment, modification or
waiver affects the rights of Warrantholder with respect to the Preferred Stock in the same manner as it affects all other holders of Preferred Stock. The Company shall provide Warrantholder with written notice of any issuance of “Additional
Shares of Common Stock” (as defined in the Company’s Charter) after the Effective Date of this Agreement, which notice shall include (a) the price at which such stock or security is to be sold, (b) the number of shares to be
issued, and (c) such other information as reasonably requested by Warrantholder. For the avoidance of doubt, there 

  
 6 

 
shall be no duplicate anti-dilution adjustment pursuant to this Section 8 and the applicable subsection of the Company’s Charter. 

(f) Notice of Adjustments. If: (i) the Company shall declare any dividend or distribution upon its stock, whether in stock,
cash, property or other securities (assuming Warrantholder consents to a dividend involving cash, property or other securities); (ii) the Company shall offer for subscription pro rata to the holders of any class of its Preferred Stock or other
convertible stock any additional shares of stock of any class or other rights; (iii) there shall be any Merger Event (including any Qualifying Merger Event); (iv) there shall be an Initial Public Offering; (v) the Company shall sell,
lease, license or otherwise transfer all or substantially all of its assets; or (vi) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall send to the
Warrantholder: (A) at least thirty (30) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend, distribution, subscription rights (specifying the date on which
the holders of Preferred Stock shall be entitled thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; (B) in the case of any such Merger Event, sale, lease, license or other
transfer of all or substantially all assets, dissolution, liquidation or winding up, at least thirty (30) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of Preferred
Stock shall be entitled to exchange their Preferred Stock for securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding up); and (C) in the case of an Initial Public Offering, the Company shall give
the Warrantholder at least thirty (30) days’ written notice prior to the effective date thereof. 
 Each such written
notice shall set forth, in reasonable detail, (i) the event requiring the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated,
(C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall be given by first class mail, postage prepaid, or by
reputable overnight courier with all charges prepaid, addressed to the Warrantholder at the address for Warrantholder set forth in the registry referred to in Section 7. 
 (g) Timely Notice. Failure to timely provide such notice required by subsection (f) above shall entitle Warrantholder to retain the benefit of the applicable notice period notwithstanding
anything to the contrary contained in any insufficient notice received by Warrantholder. For purposes of this subsection (g), and notwithstanding anything to the contrary in Section 12(g), the notice period shall begin on the date
Warrantholder actually receives a written notice containing all the information required to be provided in such subsection (f). 
 SECTION 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 
 (a)
Reservation of Preferred Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has been duly and validly reserved and, when issued in accordance with the provisions of this Agreement, will be validly issued,
fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under
state and/or federal securities laws. The Company has made available to the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance 

  
 7 

 
of certificates for shares of Preferred Stock upon exercise of this Agreement shall be made without charge to the Warrantholder for any issuance tax in respect thereof, or other cost incurred by
the Company in connection with such exercise and the related issuance of shares of Preferred Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer and the issuance and delivery
of any certificate in a name other than that of the Warrantholder. 
 (b) Due Authority. The execution and delivery by the
Company of this Agreement and the performance of all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been
duly authorized by all necessary corporate action on the part of the Company. This Agreement: (1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation or order
applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a
legal, valid and binding agreement of the Company, enforceable in accordance with its terms. 
 (c) Consents and
Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and
performance by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time
required thereby. 
 (d) Issued Securities. All issued and outstanding shares of Common Stock, Series Preferred or any
other securities of the Company have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock, Series Preferred and any other securities were issued in full compliance with all federal and
state securities laws. In addition, as of the date immediately preceding the date of this Agreement: 
 (i) The
authorized capital of the Company consists of (A) 42,000,000 shares of Common Stock, and (B) 27,598,825 shares of Series Preferred. The capitalization table attached hereto as Appendix I correctly sets forth the issued and outstanding
shares of capital stock of the Company and all warrants and options to acquire any such shares. There are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but
unissued shares of the Company’s capital stock or other securities of the Company, other than as set forth on Appendix I attached hereto. The Company has no outstanding loans to any employee, officer or director of the Company. 

(ii) In accordance with the Company’s Charter, no shareholder/stockholder of the Company has preemptive rights to
purchase new issuances of the Company’s capital stock, except as set forth in the Company’s Amended and Restated Investor Rights Agreement dated as of December 8, 2009 and as amended from time to time (the “Rights
Agreement”). 
 (e) Insurance. The Company has in full force and effect insurance policies, with extended coverage,
insuring the Company and its property and business against such losses and risks, and in such amounts, as are customary for corporations engaged in a similar business and 

  
 8 

 
similarly situated and as otherwise may be required pursuant to the terms of any other contract or agreement. 
 (f) Other Commitments to Register Securities. Except as set forth in this Agreement and the Rights Agreement, the Company is not, pursuant to the terms of any other agreement currently in
existence, under any obligation to register under the Act any of its presently outstanding securities or any of its securities which may hereafter be issued. 
 (g) Exempt Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of the Preferred Stock upon exercise of this Agreement, and the issuance
of the Common Stock upon conversion of the Preferred Stock, will each constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section 4(2) thereof, and (ii) the
qualification requirements of the applicable state securities laws. 
 (h) Compliance with Rule 144. If the Warrantholder
proposes to sell Preferred Stock issuable upon the exercise of this Agreement, or the Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the
Company shall furnish to the Warrantholder, within ten days after receipt of such request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended
from time to time. 
 (i) Information Rights. During the term of this Warrant, the Company shall deliver to the
Warrantholder (a) within one hundred eighty days after the end of each fiscal year of the Company, the annual audited financial statements of the Company certified by independent public accountants of recognized standing and (b) within
thirty days after the end of each quarter, an unaudited statement of operations and unaudited balance sheet as of the end of such fiscal quarter. The information rights provided for hereunder shall terminate and be of no further force or effect
(A) immediately prior to the consummation of an Initial Public Offering, or (B) once the Company is subject to SEC reporting obligations under Section 13(a) or Section 15(d) of the 1934 Act. 

SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder:

 (a) Investment Purpose. The right to acquire Preferred Stock or the Preferred Stock issuable upon exercise of the
Warrantholder’s rights contained herein will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution of the
same except pursuant to a registration or exemption. 
 (b) Private Issue. The Warrantholder understands (i) that the
Preferred Stock issuable upon exercise of this Agreement is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt from the registration and
qualifications requirements thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 

  
 9 

 (c) Financial Risk. The Warrantholder has such knowledge and experience in financial
and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 
 (d) Risk of No Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant to Section 12 of the Securities Exchange Act of 1934 (the “1934
Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering the securities under the Act is not in effect when it desires to sell (i) the rights to purchase Preferred Stock pursuant to
this Agreement or (ii) the Preferred Stock issuable upon exercise of the right to purchase, it may be required to hold such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder
to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder which might be made by it in reliance upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 

(e) Accredited Investor. Warrantholder is an “accredited investor” within the meaning of the Securities and Exchange Rule
501 of Regulation D, as presently in effect. 
 (f) Confidentiality. Warrantholder acknowledges that certain information
and materials provided by the Company pursuant to its obligations under this Warrant are confidential and proprietary information of the Company, and Warrantholder agrees to be bound by the confidentiality provision set forth in Section 3.3 of
the Rights Agreement. 
 (g) “Market Stand-Off”. Subject to all officers, directors, and holders of Series
Preferred of the Company being subject to the same restrictions, Warrantholder hereby agrees that it shall not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the
same economic effect as a sale (a “Market Stand-Off”), any Common Stock (or other securities) of the Company held by such Warrantholder (other than those included in the registration) (i) during the 180-day period following the
effective date of the Initial Public Offering (or such longer period, not to exceed 34 days after the expiration of the 180-day period, as the underwriters or the Company shall request in order to facilitate compliance with FINRA Rule 2711 or NYSE
Member Rule 472 or any successor or similar rule or regulation), and (ii) the 90-day period following the effective date of a registration statement of the Company filed under the Act (or such longer period, not to exceed 34 days after the
expiration of the 90-day period, as the underwriters or the Company shall request in order to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation. The underwriters of the Company’s
stock are intended third party beneficiaries of this section and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 
 SECTION 11. TRANSFERS. 
 Subject to compliance with applicable federal and
state securities laws, this Agreement and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed, provided that any successor
transferee prior to the Initial Public Offering makes the representations and covenants set forth in Section 10 and agrees in writing to be bound by the covenants, terms and conditions of this Warrant. Each taker and holder of this Agreement,
by taking or holding the same, consents and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its 

  
 10 

 
transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person
entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the
“Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company receives such Transfer Notice, the Company may treat the
registered owner hereof as the owner for all purposes. 
 SECTION 12. MISCELLANEOUS. 

(a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been
executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company. 
 (b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not
limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where Warrantholder will not have an adequate remedy at law and where damages will not be readily ascertainable. The Company
expressly agrees that it shall not oppose an application by the Warrantholder or any other person entitled to the benefit of this Agreement requiring specific performance of any or all provisions hereof or enjoining the Company from continuing to
commit any such breach of this Agreement. 
 (c) No Impairment of Rights. The Company will not, by amendment of its
Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as
may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. The foregoing notwithstanding, the Company shall not have been deemed to have impaired the Warrantholder’s rights hereunder: (i) if it
amends its Charter, or the holders of the Company’s other series of preferred stock waive rights thereunder, in a manner that does not affect the Preferred Stock differently from the effect that such amendments or waivers have generally on the
rights, preferences, privileges or restrictions of the other shares of the same class of stock, or (ii) if the Company, through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other
voluntary action, affects Warrantholder’s rights hereunder in a manner that does not affect the Preferred Stock differently from the effect that such transactions have generally on the rights, preferences, privileges or restrictions of the
other shares of the same class of stock. 
 (d) Additional Documents. The Company, upon execution of this Agreement, shall
provide the Warrantholder with certified resolutions with respect to the representations, warranties and covenants set forth in Sections 9(a) and 9(b). The Company shall also supply such other documents as the Warrantholder may from time to time
reasonably request. 
 (e) Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company
and the Warrantholder relating hereto, the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this Section 12(e), attorneys’ fees
shall include without limitation fees incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding;

  
 11 

 
(iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or
enforce any judgment. 
 (f) Severability. In the event any one or more of the provisions of this Agreement shall for any
reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision,
which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 
 (g)
Notices. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the
subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery if transmission or delivery occurs on a
business day at or before 5:00 pm in the time zone of the recipient, or, if transmission or delivery occurs on a non-business day or after such time, the first business day thereafter, or the first business day after deposit with an overnight
express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid (provided, that any Advance Request shall not be deemed received until
Lender’s actual receipt thereof), and shall be addressed to the party to be notified as follows: 
 If to Warrantholder:

 HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 

Legal Department 
 Attention: Chief Legal Officer and Manuel Henriquez 
 400 Hamilton
Avenue, Suite 310 
 Palo Alto, CA 94301 

Facsimile: 650-473-9194 
 Telephone: 650-289-3060 
 With a copy to: 

SIDLEY AUSTIN LLP 
 Attn: Pamela J. Martinson 
 1001 Page Mill Road, Bldg. 1

 Palo Alto, CA 94304 
 Facsimile: 650-565-7100 
 Telephone: 650-565-7044 

 

	 	(i)	If to the Company: 

 REVANCE THERAPEUTICS, INC. 
 Attention: David Styka 

7555 Gateway Boulevard 
 Newark, California 94560 
 Facsimile: 510-742-3401 

Telephone: 510-742-3400 

  
 12 

 or to such other address as each party may designate for itself by like notice. 

(h) Entire Agreement; Amendments. This Agreement constitute the entire agreement and understanding of the parties hereto in respect
of the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof (including
Lender’s proposal letter dated July 7, 2011). None of the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto. 
 (i) Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof. 

(j) Advice of Counsel. Each of the parties represents to each other party hereto that it has discussed (or had an opportunity to
discuss) with its counsel this Agreement and, specifically, the provisions of Sections 12(n), 12(o), 12(p). 12(q) and 12(r). 

(k) No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Agreement. 
 (l) No Waiver. No omission or delay by Warrantholder at any time to
enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which Warrantholder is entitled, nor
shall it in any way affect the right of Warrantholder to enforce such provisions thereafter. 
 (m) Survival. All
agreements, representations and warranties contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other
termination of this Agreement. 
 (n) Governing Law. This Agreement have been negotiated and delivered to Warrantholder in
the State of California, and shall have been accepted by Warrantholder in the State of California. Delivery of Preferred Stock to Warrantholder by the Company under this Agreement is due in the State of California. This Agreement shall be governed
by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

(o) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in
any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County,
State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and
(d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance
with the requirements for notice set forth in Section 12(g), and shall be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any other manner 

  
 13 

 permitted by law or shall limit the right of either party to bring proceedings in the courts
of any other jurisdiction. 
 (p) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex
financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved
by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY,
“CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons other than Borrower and Lender;
Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this
Agreement. 
 (q) Arbitration. If the Mutual Waiver of Jury Trial set forth in Section 12(p) is ineffective or
unenforceable, the parties agree that all Claims shall be submitted to binding arbitration in accordance with the commercial arbitration rules of JAMS (the “Rules”), such arbitration to occur before one arbitrator, which arbitrator shall
be a retired California state judge or a retired Federal court judge. Such proceeding shall be conducted in San Francisco County, California, with California rules of evidence and discovery applicable to such arbitration. The decision of the
arbitrator shall be binding on the parties, and shall be final and nonappealable to the maximum extent permitted by law. Any judgement rendered by the arbitrator may be entered in a court of competent jurisdiction and enforced by the prevailing
party as a final judgment of such court. 
 (r) Prearbitration Relief. In the event Claims are to be resolved by
arbitration, either party may seek from a court of competent jurisdiction identified in Section 12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by
law notwithstanding that all Claims are otherwise subject to resolution by binding arbitration. 
 (s) Counterparts. This
Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of
which counterparts shall constitute but one and the same instrument. 
 (t) Specific Performance. The parties hereto
hereby declare that it is impossible to measure in money the damages which will accrue to Warrantholder by reason of the Company’s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall
be specifically enforceable by Warrantholder. If Warrantholder institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein
that Warrantholder has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 

  
 14 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its
officers thereunto duly authorized as of the Effective Date. 
  

					
	COMPANY:	  	REVANCE THERAPEUTICS, INC.	  	
			
	            By:	  	  
	  	
			
	            Title:	  	  
	  	
			
	            Notice Address:	  	Attention: David Styka	  	
		  	7555 Gateway Boulevard	  	
		  	Newark, California 4560	  	
		  	Facsimile: 510-742-3401	  	
		  	Telephone: 510-742-3400	  	
			
	WARRANTHOLDER:	  	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.	  	
			
	            Signature:	  	  
	  	
			
	            Print Name:	  	  
	  	
			
	            Title:	  	  
	  	
			
	            Notice Address:	  	Attention:   Manuel Henriquez	  	
		  	                    Chief Legal Officer	  	
		  	400 Hamilton Avenue, Suite 310	  	
		  	Palo Alto, CA 94301	  	
		  	Facsimile: 650-473-9194	  	
		  	Telephone: 650-289-3060	  	

 [Signature Page to Warrant] 

 APPENDIX I 
 CAPITALIZATION TABLE 

  
 16 

 EXHIBIT I 
 NOTICE OF EXERCISE 
 To:
[            ] 
  

	(1)	The undersigned Warrantholder hereby elects to purchase [            ] shares of the Series
[            ] Preferred Stock of [            ], pursuant to the terms of the Agreement dated the
[            ] day of [            ,             ] (the
“Agreement”) between [            ] and the Warrantholder, and [CASH PAYMENT: tenders herewith payment of the Purchase Price in full, together with all applicable transfer taxes,
if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

  

	(2)	Please issue a certificate or certificates representing said shares of Series [        ] Preferred Stock in the name of the
undersigned or in such other name as is specified below. 

  

	(3)	The undersigned acknowledges that it has reviewed the representations, warranties and covenants contained in the Agreement and by its signature below hereby makes such
representations, warranties and covenants to the Company. 

  

					
		  	  

		  	(Name)
		
		  	  

		  	(Address)
		
	WARRANTHOLDER:	  	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
			
		  	By:	  	  

			
		  	Title:	  	  

			
		  	Date:	  	  

  
 17 

 EXHIBIT II 
 ACKNOWLEDGMENT OF EXERCISE 
 The undersigned
[            ], hereby acknowledge receipt of the “Notice of Exercise” from Hercules Technology Growth Capital, Inc., to purchase
[            ] shares of the Series [            ] Preferred Stock of
[            ], pursuant to the terms of the Agreement, and further acknowledges that [            ] shares remain subject to
purchase under the terms of the Agreement. 
  

							
	            COMPANY:	 		 	REVANCE THERAPEUTICS, INC.
				
		 		 	By:	 	  

				
		 		 	Title:	 	  

				
		 		 	Date:	 	  

  
 18 

 EXHIBIT III 
 TRANSFER NOTICE 
 (To transfer or assign the foregoing Agreement execute this form and supply
required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby
are hereby transferred and assigned to 
  

			
	  

	
	(Please Print)
		
	whose address is	 	  

	
	  

 The undersigned acknowledges that it has reviewed the representations, warranties and covenants contained in the
Agreement and by its signature below hereby makes such representations, warranties and covenants to the Company. 
  

			
		
		  	Dated:                            
                                         
                                         
                                         
                                   
		
		  	Holder’s
Signature:                                       
                                         
                                         
                                        

		
		  	Holder’s
Address:                                       
                                         
                                         
                                         
  
		
		  	                             
                                         
                                         
                                         
                                         
     
		
	Signature Guaranteed:	  	                             
                                         
                                         
                                         
                                         
     

 NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement,
without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 

  
 19EX-10.28

 Exhibit 10.28 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

FIRST AMENDMENT 
 TO

 COMPANION DIAGNOSTICS AGREEMENT 

This First Amendment (“Amendment”) shall be effective as of this 31st day of May 2013
(“Amendment Effective Date”), by and between Epizyme, Inc., having a place of business at 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139, U.S.A.
(“Epizyme”) and Eisai Co., Ltd., having a place of business at Koishikawa 4-6-10, Bunkyo-ku, Tokyo 112-8088, Japan (individually, “Eisai” and collectively with Epizyme, “Pharmaceutical
Partners”), on the one side, and Roche Molecular Systems, Inc., having a place of business at 4300 Hacienda Drive, Pleasanton, California 94588, U.S.A. (“RMS”), on the other side, as an amendment to the Companion
Diagnostics Agreement, dated 18th December 2012 (“Agreement”). Capitalized terms used in this Amendment and not defined in this Amendment shall have the meanings ascribed to
them in the Agreement. 
 WHEREAS, Epizyme, Eisai and RMS are Parties to the Agreement and desire to amend the Agreement as set forth
in this Amendment; 
 WHEREAS, Epizyme and Eisai have identified additional mutations in [**] of the EZH2 gene (“Additional
Mutations”), which the Pharmaceutical Partners desire the Assay being developed by RMS also detect; and 
 WHEREAS, RMS is
willing to modify the Assay being developed under the Agreement to include detection of the Additional Mutations, subject to the changes in the Project Plan and the Payment Plan, as well as the other provisions set forth herein. 

NOW, THEREFORE, in consideration of the agreements contained herein, and other good and valuable consideration, the receipt and
sufficiency of which each Party hereby acknowledges, the Parties hereby agree as follows: 
  

	 	1.	The definition of Assay in Section 2.5 of the Agreement is hereby amended and restated in its entirety to read as follows: 

““Assay” means an assay developed by RMS that is directed to EZH2 mutations in [**] and such other mutations as
the Parties may agree, and shall include without limitation any biological materials, associated reagents, procedures, controls, instrumentation and/or software necessary to perform the assay, but shall exclude any Samples or other materials that
the Assay is intended to test.” 
  

	 	2.	The current Project Plan under the Agreement is hereby replaced in its entirety with the amended and restated Project Plan set forth in Attachment 1 to this Amendment. 

 

	 	3.	In consideration for the additional activities required from RMS for the changes to the Project Plan, as updated in Attachment 1, the Pharmaceutical Partners agree to compensate RMS Five Hundred Thousand Dollars
($500,000.00) in addition to the payments previously set forth in the Payment Plan. This additional compensation shall become payable upon the execution of this Amendment and shall be paid following receipt of an invoice therefor from RMS in
accordance with Section 7.2 of the Agreement. 

  
 RMS – Epizyme/Eisai 

1st Amendment to CoDx Agr 

Effective Date: 31 MAY 2013 
 Page 1 of 6 

 In addition, the following adjustments shall be made to the Agreement with respect to this
additional compensation: 
  

	 	a.	The second to last sentence in Section 15.7(b) shall be amended as follows: 

 The phrase
“... in no event shall Pharmaceutical Partners be obligated to pay RMS more than an aggregate of twenty-one million dollars ($21,000,000) in milestones and Termination Fees...” shall be replaced in its entirety with “in no event
shall Pharmaceutical Partners be obligated to pay RMS more than an aggregate of twenty-one million, five hundred thousand dollars ($21,500,000) in milestones and Termination Fees...” 

 

	 	b.	The last sentence in Exhibit B, Payment Plan, shall be replaced in its entirety with the following: 

“For clarity, unless otherwise expressly agreed by the Parties in writing, in no event shall Pharmaceutical Partners be obligated to pay
RMS more than an aggregate of twenty-one million, five hundred thousand dollars ($21,500,000) in milestones (including any amount that my become payable pursuant to this paragraph) and Termination Fees under this Agreement.” 

 

	 	4.	Exhibits B and E of the Agreement are hereby further amended by replacing each reference to [**] therein with [**]. 

  

	 	5.	Exhibit C of the Agreement is hereby replaced in its entirety with the amended and restated Exhibit C set forth in Attachment 2 to this Amendment. 

 

	 	6.	 The Parties acknowledge that additional licenses or other rights to access and/or use Third Party technology or intellectual property rights may be
necessary for the development, manufacture, use or commercialization of the RMS Product, due to the development of the Assay to include detection of the Additional Mutations, and that such Third Party technology or intellectual property rights may
or may not be also needed for Pharmaceutical Partners Product. Section 5.12(a) of the Agreement is hereby amended such that Pharmaceutical Partners shall be solely responsible for obtaining and maintaining any Third Party intellectual property
rights necessary for the development, manufacture, use or commercialization of the RMS Product, to the extent such Third Party intellectual property right would not have been needed for the RMS Product but for the inclusion of the Additional
Mutations. Pharmaceutical Partners agree to provide reasonable opportunity for RMS to review and comment on any proposed terms of the Third Party agreement pursuant to which Pharmaceutical Partners obtain such rights that, in Pharmaceutical
Partners’ reasonable determination, would impose additional obligations or restrictions on RMS (beyond what is contemplated under the Agreement (as amended) for similar intellectual property rights) with respect to the RMS Product, including a
final right of approval over any terms of such agreement that would impose such additional obligations or restrictions on RMS prior to execution, such approval not to be unreasonably withheld, delayed or conditioned. In addition, Pharmaceutical
Partners agree to provide a draft of any such Third Party agreement to RMS at least [**] business days prior to execution and to reasonably consider any objections as to 

  
 RMS – Epizyme/Eisai 

1st Amendment to CoDx Agr 

Effective Date: 31 MAY 2013 
 Page 2 of 6 

	 	
obligations or restrictions that such Third Party agreement would impose on RMS with respect to the RMS Product that RMS may timely raise. Any disputes over compliance with this paragraph shall
be first resolved by the Senior Officers of the Parties pursuant to Section 4.3, and if still unresolved, then pursuant to the arbitration provisions set forth in Section 16. Once such Third Party intellectual property agreement is
finalized and executed, Pharmaceutical Partners agree to be solely responsible for any and all costs thereof to the extent relating to Third Party intellectual property rights that would not have been needed for the RMS Product but for the inclusion
of the Additional Mutations. 

  

	 	7.	The provision on “Disclosure of Funding Pursuant to State Laws” in Section 10.6 of the Agreement is hereby amended such that the heading is restated in its entirety to read “Disclosure of Funding
Pursuant to State/Federal Laws” and that two additional sentences shall be included at the end of such section as follows: 

“Each Party will be responsible for reporting, as may be required by state or federal law, any of such Party’s respective spend to
any covered recipient (as defined by the Physician Payment Sunshine Act or other similar state laws) which they make under this Agreement. In the event of a disagreement about which Party has reporting responsibility, the Parties shall discuss in
good faith. 
  

	 	8.	This Amendment is effective and shall become part of the Agreement as of the Amendment Effective Date. 

  

	 	9.	Except as provided herein, all other terms and conditions of the Agreement remain unchanged and in full force and effect. 

  

	 	10.	This Amendment may be signed in any number of counterparts (facsimile and electronic transmission included), each of which shall be deemed an original, but all of which shall constitute one and the same instrument.
After facsimile or electronic transmission, the Parties agree to execute and exchange documents with original signature. 

(Remainder of this page is left intentionally blank.) 

  
 RMS – Epizyme/Eisai 

1st Amendment to CoDx Agr 

Effective Date: 31 MAY 2013 
 Page 3 of 6 

 The Parties have executed this Amendment, by their duly authorized representatives. 

 

									
	ROCHE MOLECULAR SYSTEMS, INC.	 		 	EPIZYME, INC.
					
	By:	 	 /s/ Paul Brown
	 		 	By:	 	 /s/ Jason Rhodes

		 	(signature)	 		 		 	(signature)
					
	Name:	 	 Paul A. Brown
	 		 	Name:	 	 Jason Rhodes

		 	(printed name)	 		 		 	(printed name)
					
	Title:	 	 President and CEO
	 		 	Title:	 	 President and CFO

					
	Date:	 	 2013.10.13
	 		 	Date:	 	 10-4-13

				
		 		 		 	EISAI CO., LTD.
					
		 		 		 	By:	 	 /s/ Kenichi Nomoto

		 		 		 		 	(signature)
					
		 		 		 	Name:	 	 Kenichi Nomoto

		 		 		 		 	(printed name)
					
		 		 		 	Title:	 	 President, Oncology PCU

					
		 		 		 	Date:	 	 10-23-2013

  
 RMS – Epizyme/Eisai 

1st Amendment to CoDx Agr 

Effective Date: 31 MAY 2013 
 Page 4 of 6 

 ATTACHMENT 1 

PROJECT PLAN (updated May 2013) 

To Develop a Companion Diagnostic (CoDx) Test for EZH2 Mutation Detection to Select Patients for Treatment with E7438 

This Project Plan describes the activities and deliverables planned for a joint collaboration between Epizyme and Eisai (collectively and applicably the
Pharmaceutical Partners) and RMS to develop a companion diagnostic (CoDx) testing kit against EZH2 change of function mutations in the catalytic domain for the selection of Non-Hodgkin Lymphoma (NHL) patients for treatment with E7438. 

Background – Diagnostic Test: 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of three pages were omitted. [**] 
 Scope of this Project
Plan: 
 The Pharmaceutical Partners and RMS would like to engage in a collaboration to develop and commercialize a companion diagnostic test (RMS
Product) for the prospective selection of EZH2 mutation positive Non-Hodgkin’s Lymphoma (NHL) patients for treatment with E7438. This Project Plan describes the activities, deliverables, and estimated budget anticipated for a collaboration
between the Pharmaceutical Partners and RMS for Stage 1 – Specimen access, pre-IDE development activities with minimal set of verification studies required for IND supplement/IDE submission, Stage 2 – IVD development/core TPV studies
required for Device Authorization Application submission, Stage 3 – first pivotal registrational (open-label, single-arm) clinical trials to establish clinical utility, Stage 4 – Clinical reproducibility studies required for Device
Authorization Application submission, and Stage 5 – CE-IVD marking and Device Authorization Application submission to FDA. 
 Note: This updated
project plan and updated payment plan are based on the Key Assumptions (updated May 2013) set forth in Attachment 2. Any changes to the updated Key Assumptions may lead to a change in the project plan and payment plan. 

[**]. 
 In addition, high level budget estimates of activities
that are planned in the long term for support of a [**] will be provided to the Pharmaceutical Partners. These “ball park” estimates are based on the assumptions listed below and may be modified in the future as the scope of the project
becomes more fully defined. Modification of the scope and budget of long term activities will be agreed upon by the Pharmaceutical Partners and RMS. 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of seven pages were omitted. [**] 

  
 RMS – Epizyme/Eisai 

1st Amendment to CoDx Agr 

Effective Date: 31 MAY 2013 
 Page 5 of 6 

 ATTACHMENT 2 

KEY ASSUMPTIONS (updated May 2013) 
 As of
the Amendment Effective Date, the following items shall be deemed Key Assumptions which were used to prepare the updated Project Plan (updated May 2013) and updated Payment Plan agreed upon by the Parties: 

Note: The updated project plan (May 2013) and updated payment plan are based on the assumptions stated below. Any changes to the assumptions may lead to a
change in the project plan and payment plan. 
 [**]. 
 In
addition, high level budget estimates of activities that are planned in the long term for support of a [**] will be provided to the Pharmaceutical Partners. These “ball park” estimates are based on the assumptions listed below and may be
modified in the future as the scope of the project becomes more fully defined. Modification of the scope and budget of long term activities will be agreed upon by the Pharmaceutical Partners and RMS. 

Key Assumptions: 
 Confidential Materials omitted
and filed separately with the Securities and Exchange Commission. A total of one page was omitted. [**] 

  
 RMS – Epizyme/Eisai 

1st Amendment to CoDx Agr 

Effective Date: 31 MAY 2013 
 Page 6 of 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]